David Rodman sells shares; Mineralys Therapeutics (MLYS) Form 144 lists multiple dispositions
Rhea-AI Filing Summary
Mineralys Therapeutics (MLYS) reported insider dispositions. David Rodman reported multiple sales of Common Stock over January–March 2026, including a broker-assisted cashless exercise reported on 03/12/2026 covering 6,348 shares. The filing lists several prior dispositions in the three months before that date with individual sale dates and share counts.
Positive
- None.
Negative
- None.
Insights
Routine insider dispositions reported; timing and amounts are disclosed.
The filing lists a broker-assisted cashless exercise of 6,348 shares on
Cash-flow treatment and any use of proceeds are not detailed in the excerpt; subsequent SEC filings would show further position context or plan disclosures.
FAQ
What did Mineralys Therapeutics (MLYS) disclose in this Form 144?
How many shares were reported sold on 03/12/2026 in the MLYS Form 144?
Who is the reporting person that sold MLYS shares in the filing?
Does the Form 144 state how proceeds will be used?
Are the prior sales in the past three months detailed in the filing?